Cargando…
Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo
In this study, we characterized early biochemical changes associated with sertraline and placebo administration and changes associated with a reduction in depressive symptoms in patients with major depressive disorder (MDD). MDD patients received sertraline or placebo in a double-blind 4-week trial;...
Autores principales: | Kaddurah-Daouk, R, Bogdanov, M B, Wikoff, W R, Zhu, H, Boyle, S H, Churchill, E, Wang, Z, Rush, A J, Krishnan, R R, Pickering, E, Delnomdedieu, M, Fiehn, O |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3566722/ https://www.ncbi.nlm.nih.gov/pubmed/23340506 http://dx.doi.org/10.1038/tp.2012.142 |
Ejemplares similares
-
Pharmacometabolomics of Response to Sertraline and to Placebo in Major Depressive Disorder – Possible Role for Methoxyindole Pathway
por: Zhu, Hongjie, et al.
Publicado: (2013) -
Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept
por: Kaddurah-Daouk, R, et al.
Publicado: (2011) -
Pharmacometabolomics Reveals Racial Differences in Response to Atenolol Treatment
por: Wikoff, William R., et al.
Publicado: (2013) -
Pharmacometabolomic Signature of Ataxia SCA1 Mouse Model and Lithium Effects
por: Perroud, Bertrand, et al.
Publicado: (2013) -
Current Concepts in Pharmacometabolomics, Biomarker Discovery, and Precision Medicine
por: Beger, Richard D., et al.
Publicado: (2020)